Failure to Diagnose and Treat Hyperparathyroidism Among Patients with Hypercalcemia: Opportunities for Intervention at the Patient and Physician Level to Increase Surgical Referral

Ammar Asban, Alex Dombrowsky, Reema Mallick, Rongbing Xie, James K. Kirklin, Raymon H. Grogan, David F. Schneider, Herbert Chen, Courtney J. Balentine

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Hyperparathyroidism is both underdiagnosed and undertreated, but the reasons for these deficiencies have not been described. The purpose of this study was to identify reasons for underdiagnosis and undertreatment of hyperparathyroidism that could be addressed by targeted interventions. Materials and Methods: We identified 3,200 patients with hypercalcemia (serum calcium >10.5 mg/dL) who had parathyroid hormone (PTH) levels evaluated at our institution from 2011 to 2016. We randomly sampled 60 patients and divided them into three groups based on their PTH levels. Two independent reviewers examined clinical notes and diagnostic data to identify reasons for delayed diagnosis or referral for treatment. Results: The mean age of the patients was 61 ± 16.5 years, 68% were women, and 55% were white. Fifty percent of patients had ≥1 elevated calcium that was missed by their primary care provider. Hypercalcemia was frequently attributed to causes other than hyperparathyroidism, including diuretics (12%), calcium supplements (12%), dehydration (5%), and renal dysfunction (3%). Even when calcium and PTH were both elevated, the diagnosis was missed or delayed in 40% of patients. For 7% of patients, a nonsurgeon stated that surgery offered no benefit; 22% of patients were offered medical treatment or observation, and 8% opted not to see a surgeon. Only 20% of patients were referred for surgical evaluation, and they waited a median of 16 months before seeing a surgeon. Conclusion: To address common causes for delayed diagnosis and treatment of hyperparathyroidism, we must improve systems for recognizing hypercalcemia and better educate patients and providers about the consequences of untreated disease. Implications for Practice: This study identified reasons why patients experience delays in workup, diagnosis, and treatment of primary hyperparathyroidism. These data provide valuable information for developing interventions that increase rates of diagnosis and referral.

Original languageEnglish (US)
Pages (from-to)e828-e834
JournalOncologist
Volume24
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Hyperparathyroidism
Hypercalcemia
Referral and Consultation
Physicians
Parathyroid Hormone
Calcium
Delayed Diagnosis
Primary Hyperparathyroidism
Therapeutics
Dehydration
Diuretics
Primary Health Care
Observation
Kidney

Keywords

  • Hyperparathyroidism
  • Parathyroid hormone
  • Underdiagnosed
  • Undertreated

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Failure to Diagnose and Treat Hyperparathyroidism Among Patients with Hypercalcemia : Opportunities for Intervention at the Patient and Physician Level to Increase Surgical Referral. / Asban, Ammar; Dombrowsky, Alex; Mallick, Reema; Xie, Rongbing; Kirklin, James K.; Grogan, Raymon H.; Schneider, David F.; Chen, Herbert; Balentine, Courtney J.

In: Oncologist, Vol. 24, No. 9, 01.09.2019, p. e828-e834.

Research output: Contribution to journalArticle

Asban, Ammar ; Dombrowsky, Alex ; Mallick, Reema ; Xie, Rongbing ; Kirklin, James K. ; Grogan, Raymon H. ; Schneider, David F. ; Chen, Herbert ; Balentine, Courtney J. / Failure to Diagnose and Treat Hyperparathyroidism Among Patients with Hypercalcemia : Opportunities for Intervention at the Patient and Physician Level to Increase Surgical Referral. In: Oncologist. 2019 ; Vol. 24, No. 9. pp. e828-e834.
@article{70c6636ea54d4b8288cf151a9e37c7f5,
title = "Failure to Diagnose and Treat Hyperparathyroidism Among Patients with Hypercalcemia: Opportunities for Intervention at the Patient and Physician Level to Increase Surgical Referral",
abstract = "Background: Hyperparathyroidism is both underdiagnosed and undertreated, but the reasons for these deficiencies have not been described. The purpose of this study was to identify reasons for underdiagnosis and undertreatment of hyperparathyroidism that could be addressed by targeted interventions. Materials and Methods: We identified 3,200 patients with hypercalcemia (serum calcium >10.5 mg/dL) who had parathyroid hormone (PTH) levels evaluated at our institution from 2011 to 2016. We randomly sampled 60 patients and divided them into three groups based on their PTH levels. Two independent reviewers examined clinical notes and diagnostic data to identify reasons for delayed diagnosis or referral for treatment. Results: The mean age of the patients was 61 ± 16.5 years, 68{\%} were women, and 55{\%} were white. Fifty percent of patients had ≥1 elevated calcium that was missed by their primary care provider. Hypercalcemia was frequently attributed to causes other than hyperparathyroidism, including diuretics (12{\%}), calcium supplements (12{\%}), dehydration (5{\%}), and renal dysfunction (3{\%}). Even when calcium and PTH were both elevated, the diagnosis was missed or delayed in 40{\%} of patients. For 7{\%} of patients, a nonsurgeon stated that surgery offered no benefit; 22{\%} of patients were offered medical treatment or observation, and 8{\%} opted not to see a surgeon. Only 20{\%} of patients were referred for surgical evaluation, and they waited a median of 16 months before seeing a surgeon. Conclusion: To address common causes for delayed diagnosis and treatment of hyperparathyroidism, we must improve systems for recognizing hypercalcemia and better educate patients and providers about the consequences of untreated disease. Implications for Practice: This study identified reasons why patients experience delays in workup, diagnosis, and treatment of primary hyperparathyroidism. These data provide valuable information for developing interventions that increase rates of diagnosis and referral.",
keywords = "Hyperparathyroidism, Parathyroid hormone, Underdiagnosed, Undertreated",
author = "Ammar Asban and Alex Dombrowsky and Reema Mallick and Rongbing Xie and Kirklin, {James K.} and Grogan, {Raymon H.} and Schneider, {David F.} and Herbert Chen and Balentine, {Courtney J.}",
year = "2019",
month = "9",
day = "1",
doi = "10.1634/theoncologist.2018-0424",
language = "English (US)",
volume = "24",
pages = "e828--e834",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "9",

}

TY - JOUR

T1 - Failure to Diagnose and Treat Hyperparathyroidism Among Patients with Hypercalcemia

T2 - Opportunities for Intervention at the Patient and Physician Level to Increase Surgical Referral

AU - Asban, Ammar

AU - Dombrowsky, Alex

AU - Mallick, Reema

AU - Xie, Rongbing

AU - Kirklin, James K.

AU - Grogan, Raymon H.

AU - Schneider, David F.

AU - Chen, Herbert

AU - Balentine, Courtney J.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Background: Hyperparathyroidism is both underdiagnosed and undertreated, but the reasons for these deficiencies have not been described. The purpose of this study was to identify reasons for underdiagnosis and undertreatment of hyperparathyroidism that could be addressed by targeted interventions. Materials and Methods: We identified 3,200 patients with hypercalcemia (serum calcium >10.5 mg/dL) who had parathyroid hormone (PTH) levels evaluated at our institution from 2011 to 2016. We randomly sampled 60 patients and divided them into three groups based on their PTH levels. Two independent reviewers examined clinical notes and diagnostic data to identify reasons for delayed diagnosis or referral for treatment. Results: The mean age of the patients was 61 ± 16.5 years, 68% were women, and 55% were white. Fifty percent of patients had ≥1 elevated calcium that was missed by their primary care provider. Hypercalcemia was frequently attributed to causes other than hyperparathyroidism, including diuretics (12%), calcium supplements (12%), dehydration (5%), and renal dysfunction (3%). Even when calcium and PTH were both elevated, the diagnosis was missed or delayed in 40% of patients. For 7% of patients, a nonsurgeon stated that surgery offered no benefit; 22% of patients were offered medical treatment or observation, and 8% opted not to see a surgeon. Only 20% of patients were referred for surgical evaluation, and they waited a median of 16 months before seeing a surgeon. Conclusion: To address common causes for delayed diagnosis and treatment of hyperparathyroidism, we must improve systems for recognizing hypercalcemia and better educate patients and providers about the consequences of untreated disease. Implications for Practice: This study identified reasons why patients experience delays in workup, diagnosis, and treatment of primary hyperparathyroidism. These data provide valuable information for developing interventions that increase rates of diagnosis and referral.

AB - Background: Hyperparathyroidism is both underdiagnosed and undertreated, but the reasons for these deficiencies have not been described. The purpose of this study was to identify reasons for underdiagnosis and undertreatment of hyperparathyroidism that could be addressed by targeted interventions. Materials and Methods: We identified 3,200 patients with hypercalcemia (serum calcium >10.5 mg/dL) who had parathyroid hormone (PTH) levels evaluated at our institution from 2011 to 2016. We randomly sampled 60 patients and divided them into three groups based on their PTH levels. Two independent reviewers examined clinical notes and diagnostic data to identify reasons for delayed diagnosis or referral for treatment. Results: The mean age of the patients was 61 ± 16.5 years, 68% were women, and 55% were white. Fifty percent of patients had ≥1 elevated calcium that was missed by their primary care provider. Hypercalcemia was frequently attributed to causes other than hyperparathyroidism, including diuretics (12%), calcium supplements (12%), dehydration (5%), and renal dysfunction (3%). Even when calcium and PTH were both elevated, the diagnosis was missed or delayed in 40% of patients. For 7% of patients, a nonsurgeon stated that surgery offered no benefit; 22% of patients were offered medical treatment or observation, and 8% opted not to see a surgeon. Only 20% of patients were referred for surgical evaluation, and they waited a median of 16 months before seeing a surgeon. Conclusion: To address common causes for delayed diagnosis and treatment of hyperparathyroidism, we must improve systems for recognizing hypercalcemia and better educate patients and providers about the consequences of untreated disease. Implications for Practice: This study identified reasons why patients experience delays in workup, diagnosis, and treatment of primary hyperparathyroidism. These data provide valuable information for developing interventions that increase rates of diagnosis and referral.

KW - Hyperparathyroidism

KW - Parathyroid hormone

KW - Underdiagnosed

KW - Undertreated

UR - http://www.scopus.com/inward/record.url?scp=85065087157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065087157&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2018-0424

DO - 10.1634/theoncologist.2018-0424

M3 - Article

C2 - 31019019

AN - SCOPUS:85065087157

VL - 24

SP - e828-e834

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 9

ER -